Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant

Leuk Lymphoma. 2015 Jun;56(6):1901-2. doi: 10.3109/10428194.2014.979414. Epub 2015 Jan 14.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bortezomib / administration & dosage
  • Bortezomib / adverse effects
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Diarrhea / chemically induced
  • Humans
  • Hydroxamic Acids / administration & dosage
  • Hydroxamic Acids / adverse effects
  • Indoles / administration & dosage
  • Indoles / adverse effects
  • Induction Chemotherapy / methods
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / therapy
  • Nausea / chemically induced
  • Neutropenia / chemically induced
  • Panobinostat
  • Preoperative Period
  • Stem Cell Transplantation
  • Thrombocytopenia / chemically induced
  • Transplantation, Autologous
  • Treatment Outcome
  • Vomiting / chemically induced

Substances

  • Hydroxamic Acids
  • Indoles
  • Bortezomib
  • Dexamethasone
  • Panobinostat